Systematic review of systemic therapy for advanced or recurrent endometrial cancer.

Abstract

OBJECTIVE:

To evaluate the chemotherapeutic options for women with advanced or recurrent endometrial cancer.

METHODS:

The MEDLINE, CANCERLIT and the Cochrane Library databases were searched from 1984 to March 2005 for randomized controlled trials (RCTs) comparing chemotherapy regimens in patients with advanced or recurrent endometrial cancer. Studies were included only if patients had measurable or evaluable disease, and/or response rates were reported.

RESULTS:

Seventeen RCTs compared regimens involving chemotherapy and/or hormonal therapies. Three chemotherapy trials demonstrated a statistically significant difference in response rates between treatment arms, but only one of these trials showed a modest survival advantage. The addition of cisplatin to doxorubicin in two RCTs significantly improved response rates (1.7- to 2.5-fold higher) but did not impact on survival. In two other RCTs using cisplatin and doxorubicin as standard therapy, the addition of paclitaxel improved response rates (57% versus 34%) and median survival (15.3 versus 12.3 months) when combined with cisplatin and doxorubicin but not when combined with doxorubicin only. Toxicity was increased with the three-drug combination. Quality of life was assessed in one trial, which is currently only in abstract form. Medroxyprogesterone acetate (200 mg/day) was effective in one RCT, particularly in patients with well-differentiated, receptor-positive tumors.

CONCLUSIONS:

Combination chemotherapy with doxorubicin and cisplatin results in higher response rates than doxorubicin alone. The addition of paclitaxel to either of these regimens resulted in a small survival advantage in one trial using all three drugs. In light of the limited survival advantage associated with this regimen, the use of less toxic combinations of taxanes with carboplatin requires further study. Medroxyprogesterone acetate is useful in selected patients.

• Authors: Mark S Carey, Christine Gawlik, Michael Fung-Kee-Fung, Alexandra Chambers, Tom Oliver, Cancer Care Ontario Practice Guidelines Initiative Gynecology Cancer Disease Site Group
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 101 Issue 1 Pg. 158-67 (Apr 2006) ISSN: 0090-8258 [Print] United States
• PMID: 16434086 (Publication Type: Journal Article, Review, Systematic Review)

Chemical References

• Doxorubicin
• Medroxyprogesterone Acetate
• Cisplatin

Topics

• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Cisplatin (administration & dosage, adverse effects)
• Doxorubicin (administration & dosage, adverse effects)
• Endometrial Neoplasms (drug therapy)
• Female
• Humans
• Medroxyprogesterone Acetate (administration & dosage, adverse effects)
• Neoplasm Recurrence, Local (drug therapy)
• Randomized Controlled Trials as Topic